menu search

HCWB / HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo
HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead program, HCW9218. The preclinical data demonstrated that HCW9218 enhanced the anti-tumor efficacy of chemotherapy drugs and diminished their harmful side effects by reducing therapy-induced senescence (TIS). Read More
Posted: Jan 20 2022, 09:24
Author Name: Benzinga
Views: 102634

HCWB News  

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

By Benzinga
January 24, 2022

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in more_horizontal

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

By Benzinga
January 24, 2022

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in more_horizontal

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

By Benzinga
January 24, 2022

Masonic Cancer Center To Evaluate HCW Biologics' Bifunctional Fusion Protein In Advanced Cancers

The FDA cleared the Masonic Cancer Center, University of Minnesota to evaluate HCW Biologics Inc's (NASDAQ: HCWB) lead drug candidate, HCW9218, in more_horizontal

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

By Benzinga
January 20, 2022

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead p more_horizontal

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

By Benzinga
January 20, 2022

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead p more_horizontal

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

By Benzinga
January 20, 2022

HCW Biologics Lead Candidate Shows Preclinical Anti-Tumor Activity, Reduced Side Effects of Chemo

HCW Biologics Inc (NASDAQ: HCWB) has announced the publication of a scientific paper in Molecular Therapy highlighting preclinical data of its lead p more_horizontal


Search within

Pages Search Results: